Asset Details
Do you wish to reserve the book?
2967 Utilisation of high efficacy therapy for managing multiple sclerosis in Australia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
2967 Utilisation of high efficacy therapy for managing multiple sclerosis in Australia
Do you wish to request the book?
2967 Utilisation of high efficacy therapy for managing multiple sclerosis in Australia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
2967 Utilisation of high efficacy therapy for managing multiple sclerosis in Australia
2024
Overview
BackgroundOfatumumab is a self-administered disease modifying therapy (DMT) approved in Australia for relapsing multiple sclerosis (RMS). We have previously described a novel, high efficacy therapy (HET) classification system1 which includes ofatumumab and other monoclonal antibody therapies, ocrelizumab, natalizumab and alemtuzumab. Given the reimbursement of ofatumumab in October 2021, and in the context of this proposed classification system, we analysed the utilisation of these HETs for multiple sclerosis (MS) in Australia.MethodsDMT utilisation was analysed using an unbiased 10% sample of the Pharmaceutical Benefits Scheme Claims database as supplied by Services Australia. Patients-on-therapy (PoT) counts were attributed to the most recently prescribed DMT whilst initiations were defined as the first time a patient was prescribed a new DMT (treatment-naïve and switch) during a specified time-period.ResultsFrom September, 2021 (pre-ofatumumab reimbursement) to October, 2023, PoT for any DMT rose by 10.4% (23,070-to-25,460). In the same period, HET PoT rose by 31.3% (9,830-to-12,910), driven by increases in ofatumumab (+2,010), ocrelizumab (+1,050), and natalizumab (+110). By contrast, non-HET PoT fell by 5.2% (13,240-to-12,550), driven by fingolimod (-1,020) and dimethyl fumarate (-530). In the 12 months prior to ofatumumab reimbursement, 46.7% (2,200/4,710) of DMT initiations were HET but this proportion rose to 53.1% (2,920/5,500) in the most recent 12 month period (November-October 2023), driven by ofatumumab (1,200; 21.8%), ocrelizumab (1,090; 19.8%), and natalizumab (730; 11.5%).ConclusionsThe availability of a self-administered, at-home HET option in ofatumumab has correlated with an expansion of HET utilisation in Australia.Reference Butzkueven, et al. P755. ECTRIMS-ACTRIMS 2023.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
